Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk

Recruiting N/A Interventional Study
Chronic Lymphocytic Leukemia
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Screening
Participants needed
75 (estimated)
Sponsor
CHU de Reims · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia in western countries. CLL is most often discovered incidentally when a blood test carried out for another reason highlights an increase of subpopulation of white cells called lymphocytes. It is also sometimes diagnosed when complications such as an increase in the size of the lymph nodes or a decrease in other blood lines (red bl…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Untreated CLL patients * Patients \> 18 years of age * Patients agreing to participate to the study * Patients inured under the french social security system Exclusion Criteria: * Previously treated CLL patients * Patients protected by law
Contacts

Anne QUINQUENEL, Pr.

03.26.78.74.76

aquinquenel@chu-reims.fr

CONTACT

Amélie SERVETTAZ, Pr.

03.26.83.27.69

aservettaz@chu-reims.fr

CONTACT